Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMV055 Alone and in Combination With MMV371 in Healthy Participants
NCT07011511Phase 1Recruiting
- Sponsor
- Medicines for Malaria Venture
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mmv055 in Malaria (9 arms), sponsored by Medicines for Malaria Venture. Primary endpoints: Incidence of Adverse Events at 56 weeks, Incidence of Injection Site Reactions at 56 weeks and 8 more. Started Jun 2025; status: recruiting.
02
Drugs
mmv055
03
Conditions
Malaria
Beyond the preview
Go deeper on NCT07011511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011511.